Treatment of Phosphatidylinositol Phospholipid Disorders
AssigneeTransmolecular, Inc.
InventorsMatthew Gonda, Vernon Alvarez, Carol Grimes
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of treating cell proliferative disorders, such as cancer, with amounts of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to phosphoinositol phospholipids.
Claims56
A method of inhibiting a phosphatidylinositol signaling cascade in a cell comprising contacting a cell expressing a phosphatidylinositol phospholipid with an effective amount of an agent comprising a chlorotoxin binding domain, wherein the chlorotoxin binding domain binds to the phosphatidylinositol phospholipid.
A method of inhibiting a phosphatidylinositol signaling cascade in a cell comprising contacting a cell expressing a phosphatidylinositol phospholipid with an agent comprising a chlorotoxin binding domain, wherein the agent is not full length chlorotoxin.
A method of inhibiting the activity of a cancer cell expressing a phosphatidylinositol phospholipid on the cell surface comprising contacting the cell with an agent comprising a chlorotoxin binding domain.
A method of treating cancer in a patient in need of such treatment comprising administering an effective amount of a composition comprising an agent containing a chlorotoxin binding domain that binds to a cancer cell expressing a phosphatidylinositol phospholipid.
A method of treating cancer in a patient in need of such treatment comprising administering an effective amount of a composition comprising an agent containing a chlorotoxin binding domain that binds to a cancer cell expressing a phosphatidylinositol phospholipid, wherein the agent is not full length chlorotoxin.
A method of identifying an agent which binds to phosphatidylinositol phospholipid comprising:
- (a) contacting the phosphatidylinositol phospholipid with the agent in the presence of a polypeptide containing a chlorotoxin binding domain, and
- (b) detecting the binding of the agent to the phosphatidylinositol phospholipid.
Dependencies are inferred from the claim text.